Clinical Trial Update: AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 1/2 trial comparing AG-013736 in combination with docetaxel versus docetaxel alone in metastatic breast cancer is completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AG-013736
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-03-16